MAPK3 and ovarian carcinoma: In ovarian cancer cells, minocycline also suppressed other members of the IL-6 receptor system, including IL-6R and gp130, signaling pathways STAT3 and ERK1/2, and the downstream target myeloid cell leukemia 1 [41].